Ling Bi
Impact in
-
- Aldose Reductase and Taurine
Papers in
-
- Flavonoids in Medical Research 4
- Microbial Natural Products and Biosynthesis 2
- Co-authors
- Sadanobu Kagamimori (2 shared papers)Lijing Jiao (14 shared papers)Ling Xu (14 shared papers)Toyomi Kuwamori (1 shared paper)Xiulan Su (1 shared paper)Yabin Gong (10 shared papers)Jialin Yao (7 shared papers)Qihan Dong (7 shared papers)
In The Last Decade
Ling Bi
28 papers receiving 627 citations
Peers
Comparison fields: 5 of 80
- Cell Biology 109
- Cancer Research 70
- Pharmacology 81
- Complementary and alternative medicine 38
- Pharmacology 40
Countries citing papers authored by Ling Bi
This map shows the geographic impact of Ling Bi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ling Bi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ling Bi more than expected).
Fields of papers citing papers by Ling Bi
This network shows the impact of papers produced by Ling Bi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ling Bi. The network helps show where Ling Bi may publish in the future.
Co-authors
The 25 scholars most cited alongside Ling Bi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 31 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2003 | 169 | |
| 2 | 2018 | 49 | |
| 3 | 2022 | 47 | |
| 4 | 2019 | 44 | |
| 5 | 2020 | 30 | |
| 6 | 2018 | 28 | |
| 7 | 2014 | 28 | |
| 8 | 2019 | 26 | |
| 9 | 2021 | 26 | |
| 10 | 2021 | 25 | |
| 11 | 2018 | 25 | |
| 12 | 2020 | 20 | |
| 13 | 2017 | 18 | |
| 14 | 2019 | 16 | |
| 15 | 2003 | 16 | |
| 16 | 2022 | 15 | |
| 17 | 2024 | 10 | |
| 18 | 2020 | 10 | |
| 19 | 2024 | 10 | |
| 20 | 2024 | 6 |
About Ling Bi
Ling Bi is a scholar working on Cancer Research, Pharmacology, Pulmonary and Respiratory Medicine, Oncology and Pathology and Forensic Medicine, having authored 31 papers that have together received 642 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (6 papers), Flavonoids in Medical Research (4 papers), Ubiquitin and proteasome pathways (4 papers), Lung Cancer Diagnosis and Treatment (3 papers), RNA modifications and cancer (3 papers), Lung Cancer Research Studies (2 papers), Microbial Natural Products and Biosynthesis (2 papers) and Immune cells in cancer (2 papers). The work is most often cited by research in Cell Biology (109 citations), Cancer Research (70 citations), Pharmacology (81 citations), Complementary and alternative medicine (38 citations) and Pharmacology (40 citations). Ling Bi has collaborated with scholars based in China, Australia and Thailand. Frequent co-authors include Sadanobu Kagamimori, Lijing Jiao, Ling Xu, Toyomi Kuwamori, Xiulan Su, Yabin Gong, Jialin Yao, Qihan Dong, Yan Lu and Wenxiao Yang. Their work appears in journals such as Frontiers in Pharmacology, Journal of Cellular and Molecular Medicine, Amino Acids, Biological Procedures Online and Integrative Cancer Therapies.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.